CG OncologyCGON -2.12%12 Days Inventory is 47.10 as of Mar. 2026, which is 62% below its 10-year median of 122.92. GuruFocus rates CGON with a GF Score™ of 12/100. The stock has 5 warning signs investors should review. Among 638 Biotechnology companies, CG Oncology ranks better than 80.09% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). CG Oncology's Average Total Inventories for the
three
months ended in Mar. 2026 was $1.53 Mil. CG Oncology's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $2.96 Mil.
Hence, CG Oncology's Days Inventory for the
three
months ended in Mar. 2026 was 47.10.
The historical rank and industry rank for CG Oncology's Days Inventory or its related term are showing as below:
CGON'
s Days Inventory Range Over the Past 10 Years
Min: 72.9 Med: 122.92 Max: 122.92
Current: 72.9
During the past 5 years, CG Oncology's highest Days Inventory was 122.92. The lowest was 72.90. And the median was 122.92.
CGON's Days Inventory is ranked better than 80.09% of 638
companies
in the Biotechnology industry
Industry Median: 183.875
vs CGON: 72.90
CG Oncology's Days Inventory
increased
from Mar. 2025 (0.00) to Mar. 2026 (47.10).
It might indicate that CG Oncology's sales slowed down.
Warning Sign:
If a company builds up inventory, it may mean it is having difficulties selling its goods.
Inventory Turnover measures how fast the company turns over its inventory within a year.
CG Oncology's Inventory Turnover for the
three
months ended in Mar. 2026 was 1.94.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
CG Oncology's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 1.41.
CG Oncology (NAS:CGON) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
CG Oncology's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
CG Oncology's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
CG Oncology Days Inventory Related Terms
CG Oncology Days Inventory Historical Data
* Premium members only.
The historical data trend for CG Oncology's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CGON vs COGT, SRRK, LGND: Days Inventory Comparison
For the Biotechnology subindustry, CG Oncology's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CG Oncology Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CG Oncology's Days Inventory distribution charts can be found below:
* The bar in red indicates where CG Oncology's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CG Oncology (CGON) has a Days Inventory of 47.10 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on CG Oncology and its competitors. This is 62% below median its historical median of 122.92. Over the past decade, CG Oncology's Days Inventory has ranged from 72.90 to 122.92. According to the industry distribution chart, CG Oncology ranks #127 out of 638 companies in the Biotechnology industry, placing it in the top 19.9%.
Is CG Oncology's Days Inventory too high?
CG Oncology's current Days Inventory of 47.10 is 62% below median its 10-year median of 122.92. Over the past 10 years, this metric has ranged from a low of 72.90 to a high of 122.92. The Biotechnology industry median Days Inventory is 183.88. CG Oncology's value of 47.10 is 74.4% below this industry median. Based on the distribution chart, CG Oncology ranks #127 out of 638 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, CG Oncology has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does CG Oncology's Days Inventory compare to COGT and SRRK?
According to the Biotechnology industry distribution chart, CG Oncology ranks #127 out of 638 companies for Days Inventory. This places CG Oncology in the top 20% of its industry — outperforming the majority of peers. The industry median Days Inventory is 183.88. CG Oncology's value of 47.10 is 74.4% below this benchmark. Historically, CG Oncology's own Days Inventory has ranged from 72.90 to 122.92 over the past decade. While the company's 10-year median is 122.92 vs. the industry median of 183.88, CG Oncology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.88, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CG Oncology's current Days Inventory of 47.10 is 74.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on CG Oncology and its competitors. For the Biotechnology industry, the median Days Inventory is 183.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CG Oncology's current Days Inventory is 47.10, which is 62% below median its own 10-year median of 122.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CG Oncology stock overvalued right now?
CG Oncology (CGON) has a current Days Inventory of 47.10. The current Days Inventory is 47.10, which is 62% below median its 10-year median of 122.92 and 74.4% below the Biotechnology industry median of 183.88. CG Oncology's overall GF Score™ is 12/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For CG Oncology (CGON), the current Days Inventory is 47.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
12GF Score
Get the complete analysis for CGON
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CGON has been successfully added to your 
